Iterum Therapeutics plc

NasdaqCM:ITRM Stock Report

Mkt Cap: US$14.6m

Iterum Therapeutics Past Performance

How has Iterum Therapeutics performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ITRM is currently unprofitable.

Growing Profit Margin: ITRM is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ITRM is unprofitable, but has reduced losses over the past 5 years at a rate of 0.6% per year.

Accelerating Growth: Unable to compare ITRM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ITRM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7%).

Return on Equity

High ROE: ITRM has a negative Return on Equity (-133.72%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies